PHARMING SUBMITS MARKETING AUTHORISATION APPLICATION FOR RECOMBINANT HUMAN C1 INHIBITOR IN EUROPE

Biotech company Pharming Group N.V. ("Pharming" or "the Company") (PHARM.AS) announced it has submitted the Marketing Authorization Application (MAA) for recombinant human C1 inhibitor (rhC1INH) to the European Medicines Agency (EMEA) for the treatment of acute attacks of hereditary angioedema (HAE).

Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5345/101/)